TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 788739

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 50 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 100 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 200 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 300 mg/day
Number of subjects: 7
Study: 30760127

Group type: EXPERIMENTAL
Intervention: English listeners estimating age from English speakers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Japanese listeners estimating age from English speakers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Japanese listeners estimating age from Japanese speakers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: English listeners estimating age from Japanese speakers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups of listeners estimating age based on speaker characteristics
Number of subjects: 0
Study: 31388932

Group type: EXPERIMENTAL
Intervention: Carfilzomib plus dexamethasone (Kd) twice-weekly (56 mg/m2)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Bortezomib plus dexamethasone (Vd)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Carfilzomib plus dexamethasone (Kd) once-weekly (70 mg/m2)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Carfilzomib plus dexamethasone (Kd) twice-weekly (27 mg/m2)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Carfilzomib (both dosing regimens)
Number of subjects: 158
Study: 29207479

Group type: EXPERIMENTAL
Intervention: Group A: mother's own milk (MOM) and donor milk (unfortified)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Group B: MOM (unfortified) and preterm formula
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Group C: MOM (start fortification >50 mL/day) and preterm formula
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Nutritional intake of phosphorus (P)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Nutritional intake of calcium (Ca)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Interaction between Ca and P intake
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Volume of human milk per kg during the first 10 days
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Higher intakes of Ca and P during the first 10 days
Number of subjects: 109
Study: 25581604

Group type: EXPERIMENTAL
Intervention: NLFU + Standard Care (SC)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: NLFU + SC
Number of subjects: 112

Group type: COMPARATOR
Intervention: SC
Number of subjects: 112
Study: 23641026

Group type: EXPERIMENTAL
Intervention: Dynamic Gait Index (DGI)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 25-Foot Timed Walk Test
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Impact Scale (psychological subscale)
Number of subjects: 81
Study: 22283892

Group type: EXPERIMENTAL
Intervention: 4 months daily rifampin (4RMP)
Number of subjects: 20000

Group type: COMPARATOR
Intervention: 9 months daily isoniazid (9INH)
Number of subjects: 20000

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 20000
Study: 19585672

Group type: EXPERIMENTAL
Intervention: Daytime sleep for 1 hour
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wake condition (control)
Number of subjects: 0
Study: 16389540

Group type: COMPARATOR
Intervention: Placebo treatment for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gram-negative organisms
Number of subjects: 0
Study: 15541850

Group type: EXPERIMENTAL
Intervention: Rhophylac 300 (300 microg dose) administered either intravenously or intramuscularly
Number of subjects: 432
Study: 11110260

Group type: EXPERIMENTAL
Intervention: Adhesion preventing techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard surgical intervention
Number of subjects: 0
Study: 9372670

Group type: EXPERIMENTAL
Intervention: Nebulized DSCG 20 mg every 6 hours from Day 3 to Day 28
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (2 cc NS) every 6 hours from Day 3 to Day 28
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nebulized DSCG 20 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (2 cc NS)
Number of subjects: 26
Study: 1609045

Group type: EXPERIMENTAL
Intervention: Guanfacine 0.5 mg daily
Number of subjects: 29
Study: 3980808

Group type: EXPERIMENTAL
Intervention: Unna's boots
Number of subjects: 21

Group type: COMPARATOR
Intervention: Elastic support stockings
Number of subjects: 21
Study: 3592142

Group type: EXPERIMENTAL
Intervention: Aerosolized MgSO4
Number of subjects: 9

Group type: COMPARATOR
Intervention: NaCl (saline)
Number of subjects: 9
Study: 31943843

Group type: EXPERIMENTAL
Intervention: U5MTase (uracil‐5‐methyltransferase) identified in Plasmodium falciparum (Pf, strain Pf3D7)
Number of subjects: 300000000

Group type: EXPERIMENTAL
Intervention: In silico drug screening for potential inhibitory drug molecules
Number of subjects: 300000000
Study: 30427061

Group type: EXPERIMENTAL
Intervention: Anterior thalamic nucleus deep brain stimulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no stimulation during the first 6 months)
Number of subjects: 18
Study: 27281754

Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery
Number of subjects: 33
Study: 26645515

Group type: EXPERIMENTAL
Intervention: Moxibustion therapy (Group A)
Number of subjects: 56
Study: 22481046

Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 1421

Group type: COMPARATOR
Intervention: IVUS-non-guided PCI
Number of subjects: 1421
Study: 21233256

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy management and/or disease management including motivational interviewing (MI) counseling every 6 months over 2 years
Number of subjects: 750
Study: 18274885

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine (SP)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 352
Study: 16927525

Group type: EXPERIMENTAL
Intervention: Iscador Quercus special (IQ; rich in mistletoe lectin)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Iscador Pinus (IP; poor in mistletoe lectin but rich in viscotoxin)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 47
Study: 12675544

Group type: EXPERIMENTAL
Intervention: Individualized 3-hour training session on using the World Wide Web to research patient-related questions
Number of subjects: 80
Study: 10922131

Group type: EXPERIMENTAL
Intervention: Combination therapy (salmeterol 50 microg twice daily + fluticasone propionate 100 microg twice daily)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Concurrent therapy (salmeterol 50 microg twice daily + fluticasone propionate 100 microg twice daily via separate inhalers)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 257

Group type: COMPARATOR
Intervention: Concurrent therapy
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 257
Study: 8880836

Group type: COMPARATOR
Intervention: Crohn's disease patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Crohn's disease and IBS patients
Number of subjects: 30
Study: 1563299

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Local infiltration anaesthesia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Local infiltration anaesthesia plus local wound hypothermia with ice bags
Number of subjects: 24
Study: 3906941

Group type: EXPERIMENTAL
Intervention: Human antilipopolysaccharide (anti-LPS)-specific globulin (LG-1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 31779994

Group type: EXPERIMENTAL
Intervention: Shenmai injection (100 ml/day) for 9.28±3.75 days followed by Shenmai capsule (3.6 g/day) for 30 days in addition to cardiac rehabilitation
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (only cardiac rehabilitation)
Number of subjects: 166
Study: 29717512

Group type: EXPERIMENTAL
Intervention: Hybrid-sirolimus eluting stents (SES)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Everolimus eluting stents (EES)
Number of subjects: 330
Study: 27806972

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) 1315 mg catechins (843 mg EGCG), 4 capsules daily for 12 months
Number of subjects: 936

Group type: COMPARATOR
Intervention: Placebo, 4 capsules daily for 12 months
Number of subjects: 936
Study: 25024178

Group type: EXPERIMENTAL
Intervention: Choosing between similarly high-valued products
Number of subjects: 0

Group type: COMPARATOR
Intervention: No high-value option
Number of subjects: 0

Group type: COMPARATOR
Intervention: Only one option was highly valued
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dorsal mPFC activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ventral regions activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activity levels across individual items
Number of subjects: 0
Study: 23648200

Group type: EXPERIMENTAL
Intervention: Autologous platelet adhesives (APA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (low risk group undergoing radiation only)
Number of subjects: 0
Study: 20523295

Group type: EXPERIMENTAL
Intervention: Digital drainage system with fast-track chest tube removal protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional drainage system with subjective visual air leak assessment
Number of subjects: 0
Study: 18473339

Group type: EXPERIMENTAL
Intervention: Rational-emotive behavior therapy (REBT)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Pharmacotherapy (fluoxetine)
Number of subjects: 170
Study: 16026803

Group type: EXPERIMENTAL
Intervention: IFN beta-1a, 22 or 44 mcg subcutaneously three times weekly during years 3 and 4
Number of subjects: 0
Study: 12148100

Group type: EXPERIMENTAL
Intervention: Thermoneutral dialysis (energy flow rate: DeltaE = -0.22 +/- 0.29 kJ/kg x h)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Isothermic dialysis (energy flow rate: DeltaE = -0.90 +/- 0.35 kJ/kg x h)
Number of subjects: 116
Study: 9710006

Group type: COMPARATOR
Intervention: HLA-DRB1*0803 in C. jejuni + GM1 + GBS group
Number of subjects: 81

Group type: COMPARATOR
Intervention: TCR, HLA class I and II genetic markers
Number of subjects: 81
Study: 7609864

Group type: EXPERIMENTAL
Intervention: B-vitamins (thiamine diphosphate 100 mg, pyridoxsine-HCl 200 mg, cyanocobalamin 20 micrograms, p.o.)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Diclofenac (diclofenac-Na, 50 mg, p.o.)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 2147029

Group type: EXPERIMENTAL
Intervention: Isradipine, 14.5 mg once daily
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 381093

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg four times daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Antacid (Mylanta II, 30 ml four times daily and PRN)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Antacid
Number of subjects: 15
Study: 30285054

Group type: EXPERIMENTAL
Intervention: Low-dose amitriptyline (25 mg/d)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Active comparator (benztropine mesylate, 1 mg/d)
Number of subjects: 146
Study: 26868507

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe
Number of subjects: 39
Study: 25068637

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg every 4 weeks for 20 weeks, then as needed (PRN) thereafter.
Number of subjects: 177

Group type: COMPARATOR
Intervention: Sham treatment every 4 weeks for 20 weeks, then sham thereafter.
Number of subjects: 177
Study: 22343361

Group type: EXPERIMENTAL
Intervention: 3-5 days of antibiotic treatment (group 1)
Number of subjects: 66

Group type: COMPARATOR
Intervention: 7-10 days of antibiotic treatment (group 2)
Number of subjects: 66
Study: 20357312

Group type: EXPERIMENTAL
Intervention: Early group intervention based on cognitive‐behavioural principles
Number of subjects: 217

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 217
Study: 17425757

Group type: EXPERIMENTAL
Intervention: Lombotomy mini-incision technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subcostal mini-incision technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 60
Study: 15728647

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 3137

Group type: COMPARATOR
Intervention: No statin treatment
Number of subjects: 3137
Study: 12195449

Group type: EXPERIMENTAL
Intervention: Comprehensive outpatient rehabilitative treatment for 6 weeks, 6 days a week.
Number of subjects: 111

Group type: COMPARATOR
Intervention: Waiting list control group with self-exercises at home.
Number of subjects: 111
Study: 9783376

Group type: EXPERIMENTAL
Intervention: 0.25 mg GTN
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 0.5 mg GTN
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 97
Study: 7826118

Group type: EXPERIMENTAL
Intervention: Needle aspiration
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no aspiration)
Number of subjects: 77
Study: 3046407

Group type: EXPERIMENTAL
Intervention: Birch pollen extract alone (n = 24)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mixture of alder, birch and hazel pollen extracts (n = 27)
Number of subjects: 51
Study: 30005989

Group type: EXPERIMENTAL
Intervention: Microbial cellulose sheets
Number of subjects: 40

Group type: COMPARATOR
Intervention: Silver sulphadiazine cream 10mg/g
Number of subjects: 40
Study: 27001317

Group type: EXPERIMENTAL
Intervention: Emollient balm applied twice a day for 28 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Emollient balm
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (hygiene product only)
Number of subjects: 54
Study: 26313719

Group type: EXPERIMENTAL
Intervention: 500 mg intravenous hydrocortisone administered during anesthetic induction
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no hydrocortisone administered)
Number of subjects: 22
Study: 23210695

Group type: EXPERIMENTAL
Intervention: Cryoballoon (Cryo) ablation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cryoballoon (Cryo) ablation without RF
Number of subjects: 80

Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation only
Number of subjects: 80
Study: 21835638

Group type: EXPERIMENTAL
Intervention: GA + TEA
Number of subjects: 30

Group type: COMPARATOR
Intervention: GA
Number of subjects: 30
Study: 18178205

Group type: EXPERIMENTAL
Intervention: Initial examination of ACF detection
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Follow-up examination after 1 year
Number of subjects: 78
Study: 17131714

Group type: COMPARATOR
Intervention: Placebo dentifrice (0 ppm F; PD)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Dose response control dentifrice (250 ppm F; DD)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Clinically tested fluoride dentifrice (1100 ppm F; FD)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Test dentifrice (1150 ppm F + 5% KNO3; TD)
Number of subjects: 13
Study: 12486753

Group type: EXPERIMENTAL
Intervention: New method for defining comparable case groups using an estimate of the mean sojourn time (mean preclinical duration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New method for defining comparable case groups
Number of subjects: 0
Study: 10857963

Group type: EXPERIMENTAL
Intervention: Depressive symptoms (CES-D > or =22)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Greater depressive symptoms
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 183
Study: 9104712

Group type: COMPARATOR
Intervention: Inlay with Panavia Ex resin (isthmus width of one third the intercuspal distance)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Inlay with Panavia Ex resin (isthmus width equal to that in group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Inlay with Panavia Ex resin (isthmus width of half the intercuspal distance)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Inlay with Panavia Ex resin (isthmus width equal to group 3 with lingual and proximal preparation)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Onlay cemented with zinc phosphate cement (positive control)
Number of subjects: 50
Study: 8064017

Group type: EXPERIMENTAL
Intervention: Tegratol (carbamazepine)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control periods (before and after drug administration)
Number of subjects: 1
Study: 3055922

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg nightly (Stratum 1)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily (Stratum 1)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg nightly (Stratum 2)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily (Stratum 2)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Lovastatin (both strata)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Gemfibrozil (both strata)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 334
Study: 31770446

Group type: COMPARATOR
Intervention: Periarticular injection (PAI) with extended-release bupivacaine 266 mg and 20 mL of 0.5% bupivacaine hydrochloride
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB) with extended-release bupivacaine 266 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 70

Group type: COMPARATOR
Intervention: PAI group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: ACB group
Number of subjects: 70
Study: 31719005

Group type: EXPERIMENTAL
Intervention: High-dose vitamin C (5 g intravenous before anesthesia induction and 5 g in cardioplegic solution)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-dose vitamin C
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (placebo - normal saline)
Number of subjects: 50
Study: 28749549

Group type: EXPERIMENTAL
Intervention: Rituximab (2 biweekly infusions of 1g each)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 24
Study: 25008903

Group type: EXPERIMENTAL
Intervention: Tdap1 booster
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Tdap5 booster
Number of subjects: 34
Study: 22416896

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) incorporated into a structured education programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urine glucose monitoring incorporated into a structured education programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urine glucose monitoring
Number of subjects: 0
Study: 20609381

Group type: EXPERIMENTAL
Intervention: Task-specific group (3 additional sessions of serial targeting practice)
Number of subjects: 18

Group type: COMPARATOR
Intervention: General arm use group (3 training sessions of increased but non-task specific use of the hemiparetic arm)
Number of subjects: 18
Study: 18051001

Group type: EXPERIMENTAL
Intervention: PREMA (PM)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Opalustre (OP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both products (PREMA and Opalustre)
Number of subjects: 36
Study: 16040019

Group type: EXPERIMENTAL
Intervention: Cell based dressing with living allogenic keratinocytes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Microcarriers kept in culture medium overnight (Control)
Number of subjects: 40
Study: 11911626

Group type: EXPERIMENTAL
Intervention: Standard cannulation of the ascending aorta
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cannulation of the distal aortic arch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perfusionist interventions
Number of subjects: 0
Study: 11820954

Group type: EXPERIMENTAL
Intervention: 2HRZS/4HR plus vaccine of Mycobacterium vaccae
Number of subjects: 70

Group type: COMPARATOR
Intervention: 2HRZS/4HR
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 4-6 sensitive antituberculous drugs and vaccine of Mycobacterium vaccae
Number of subjects: 70
Study: 7852453

Group type: EXPERIMENTAL
Intervention: Group I (dressings and variable ambient temperature for comfort)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group II (without dressings and variable ambient temperature for comfort)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group III (without dressings and ambient temperature of 25 degrees C, electromagnetic heaters for comfort)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group IV (healthy volunteers)
Number of subjects: 20
Study: 2682215

Group type: EXPERIMENTAL
Intervention: Sinemet CR4 (50/200)
Number of subjects: 20
Study: 1249190

Group type: EXPERIMENTAL
Intervention: Total fasting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No carbohydrate hypocaloric diet (800 kcal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isocaloric diets with at least 50 g of carbohydrate
Number of subjects: 0
Study: 31258526

Group type: EXPERIMENTAL
Intervention: Allogeneic adipose mesenchymal stem cells (darvadstrocel, formerly Cx601)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro complement-dependent cytotoxicity (CDC) studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adipose mesenchymal stem cells (ASC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depletion of CD46
Number of subjects: 0
Study: 28638273

Group type: EXPERIMENTAL
Intervention: Nefopam infusion (0.3 mg/kg bolus followed by 65 µg/kg/h infusion)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.3 mg/kg bolus followed by 180 µg/kg/h infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control group, equal to ketamine infusion)
Number of subjects: 60